The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Triple Negative Breast Cancer
Interventions: DRUG: Sintilimab|DRUG: Anlotinib|DRUG: Nab paclitaxel|DRUG: Carboplatin|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Guangdong Provincial People's Hospital